2017 France Tumor Markers: Supplier Shares by Test, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review, Emerging Opportunities

March 2017 | 585 pages | ID: F891943E79EEN
Venture Planning Group

Abstracts

Complete report $6,800. DataPack (test volumes, sales forecasts, supplier shares) $4,350.

VPGMarketResearch.coms new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the French cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Cancer Diagnostic Tests—Over 200 current and emerging assays including:ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

Sales and market shares of major suppliers, by individual cancer diagnostic test.

Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:- Hospitals- Commercial/Private Laboratories- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.- Cancer statistics, etiology and recent developments.Current and Emerging Products

• Review of over 200 current and emerging cancer diagnostic tests, including:
• Biochemical Markers
• Oncogenes
• Growth Factors
• Hormones
• Colony Stimulating Factors
• Lymphokines
• Immunohistochemical Stains, and others.
• Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

• Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
• Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contains 585 pages and 95 tables

Contents

1. INTRODUCTION

2. WORLDWIDE MARKET OVERVIEW

1. MARKET OVERVIEW
2. WORLDWIDE MARKET STRUCTURE
3. WORLDWIDE MARKET SIZE AND GROWTH

3. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

4. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

5. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies

6. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

7. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology
  1. BREAST CANCER
  2. LUNG CANCER
  3. COLON AND RECTUM CANCER
  4. PROSTATE CANCER
  5. STOMACH CANCER
  6. LEUKEMIA
  7. LYMPHOMA
  8. ORAL CANCER
  9. SKIN CANCER
  10. UTERINE CANCER
  11. OVARIAN CANCER
  12. BLADDER CANCER
B. Major Current And Emerging Cancer Diagnostic Tests
  1. INTRODUCTION
  2. TUMOR MARKER CLASSIFICATION
  3. ACTH
  4. ALPHA-FETOPROTEIN (AFP)
  5. BETA-2 MICROGLOBULIN
  6. CA 15-3/27.29
  7. CA 19-9
  8. CA-125
  9. CALCITONIN
  10. CARCINOEMBRIONIC ANTIGEN (CEA)
  11. ESTROGEN AND PROGESTERONE RECEPTORS
  12. FERRITIN
  13. GASTRIN
  14. HUMAN CHORIONIC GONADOTROPIN (HCG)
  15. INSULIN
  16. NSE
  17. OCCULT BLOOD
  18. PAP SMEAR/HPV
  19. PROSTATIC ACID PHOSPHATASE (PAP)
  20. PROSTATE-SPECIFIC ANTIGEN (PSA)
  21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
  22. T AND B LYMPHOCYTES
  23. TDT
  24. THYROGLOBULIN
  25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
  26. BIOCHEMICAL TUMOR MARKERS
  27. ONCOGENES
    Abl/abl-bcr
    AIB1
    BCL-2
    BRCA1
    CD44
    C-fos
    C-myb
    C-myc
    CYP-17
    Erb-B
    HPC1
    N-myc
    P40
    P51
    P53
    PIK3CA
    PTI-1
    Ras
    Reg
    Sis
    Src
  28. POLYPEPTIDE GROWTH FACTORS
    Basic Fibroblast Growth Factor
    Beta-TGF
    Cachectin (TNT)
    Calmodulin
    ECFR
    Nerve Growth Factor (NGF)
    Epidermal Growth Factor (EGF)
    Ornithine Decarboxylase
    Transferrin
    Transforming Growth Factor-Alpha
  29. ECTOPIC HORMONES
  30. COLONY STIMULATING FACTORS
  31. LYMPHOKINES
    Alpha-Interferon
    B Cell Growth Factors
    B Cell Growth Factor (BCGF)
    Gamma-Interferon
    Interleukin-1 (IL-1)
    Macrophage Activating Factor
  32. IMMUNOHISTOCHEMICAL STAINS
  33. EMERGING TUMOR MARKERS
    N-Acetylglucosamine
    Actin
    Alpha-Actin
    Antineuronal Antibodies
    7B2
    B72.3
    Bax
    BCD-F9
    BLCA-4
    Blood Group Antigens A, B, H
    CA
    CA 72-4/TAG-72
    CA
    CA-242
    CA-549
    CAM
    CAR-3
    Cathepsin-D
    Chromogranin A and B
    Cluster 1 Antigen
    Cluster-5/5A Antigen
    CTA
    CU18
    DR-70
    DU-PAN-2
    Endometrial Bleeding Associated Factor
    Endostatin
    Epithelial Membrane Antigen
    Feulgen Hydrolysis
    Fibronectin
    FSH
    (1->3)-L-fucosyltransferase
    Gastrin-Releasing Peptide (GRP)
    GDCFP-15
    Glucagon
    Glycoamines
    H23
    Her-2
    Human Carcinoma Antigen
    HPA
    HSP27
    Intermediate Filaments
    Cytokeratins/CK18/Cyfra 21-1
    Desmin
    Gliofibrillary Acid Protein
    Neurofilaments
    Vimentin
    KA
    Kinases
    KP16D3
    LAI
    Leukocyte Common Antigen
    Lewis Antigens
    Lysophosphatidic Acid (LPA)
    Ma 695/Ma
    MABDF3
    MAG
    ME1
    Minactivin
    MN/CA9
    MSA
    Mucin Cancer Antigen (MCA)
    Multiple Tumor Suppressor
    Myosin
    NEA-130
    NMP22
    OA-519
    Opiod Peptides
    P-glycoprotein
    Pancreatic Oncofetal Antigen (POA)
    Placental Lactogen
    PR92
    Proliferative Index, Ki-67
    Px
    RB Inactivation/Deletion
    Ret
    SCCL
    Selectin
    Sialic Acid
    Sialyl SSEA-1/SLX
    SN10
    Somatostatin
    TA-90
    TABA
    Tachykinin
    TAG
    TPS
    Troponin
    Tubulin
    VCAM
    VEGF
    Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
  1. MONOCLONAL AND POLYCLONAL ANTIBODIES
  2. IMMUNOASSAYS
  3. MOLECULAR DIAGNOSTICS
  4. CHROMOSOME ANALYSIS
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. ARTIFICIAL INTELLIGENCE
  6. FLOW CYTOMETRY
  7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)
  8. BIOSENSORS
  9. COMPETING/COMPLEMENTING TECHNOLOGIES
E. Personal Testing

8. FRANCE CANCER DIAGNOSTICS MARKET

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test

9. COMPETITIVE PROFILES

Abbott
AdnaGen/Alere
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio
Guided Therapeutics
Hologic/Gen-Probe
Kreatech/Leica
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Thermo
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

10. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

List Of Tables

LIST OF TABLES

Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis
Executive Summary Table: France, Total Cancer Diagnostic Test Volume and Sales Forecast by Market Segment
France, Estimated Cancer Death Rates Per 100, 000 Population
France, Laboratories Performing Tumor Marker Tests by Market Segment
France, Hospital Laboratories Performing Tumor Marker Tests by Bed Size
France, Commercial/Private Laboratories Performing Tumor Markers by Annual Test Volume
France, Total Tumor Marker Test Volume Forecast by Market Segment
France, All Market Segments Major Tumor Marker Test Volume Forecast
France, Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
France, Commercial/Private Laboratories Marker Test Volume Forecast
France, Total Tumor Marker Sales Major Tumor Forecast by Market Segment
France, All Market Segments Major Tumor Marker Sales Forecast by Test
France, Hospital Laboratories Major Tumor Marker Sales Forecast by Test
France, Commercial/Private Laboratories Cancer Diagnostics Market Forecast by Test
France, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
France, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
France, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
France, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
France, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market
France, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
France, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
France, Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
France, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
France, Colon-Specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment
France, Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
France, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
France, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
France, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
France, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
France, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
France, Interferons Test Volume and Diagnostics Sales Forecast by Market Segment
France, Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment
France, Lymphocyte Subtyping Test Volume And Diagnostics Sales Forecast by Market Segment
France, NSE Test Volume and Diagnostics Sales Forecast by Market Segment
France, Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
France, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
France, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
France, Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
France, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
France, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
France, Progesterone Receptor Test Volume And Diagnostics Sales Forecast by Market Segment
France, PAP Test Volume and Diagnostics Sales Forecast by Market Segment
France, PSA Test Volume and Diagnostics Sales Forecast by Market Segment
France, S-100 Protein Test Volume and Sales Diagnostics Sales Forecast by Market Segment
France, Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
France, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
France, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
France, TDT Test Volume and Diagnostics Sales Forecast by Market Segment
France, Thymidine Kinase Test Volume And Diagnostics Sales Forecast by Market Segment
France, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
France, TPA Test Volume and Diagnostics Sales Forecast by Market Segment
France, Total Tumor Marker Sales By Major Suppliers
France, AFP Testing Market Diagnostics Sales by Major Supplier
France, CA 15-3 Testing Market Diagnostics Sales by Major Supplier
France, CA 19-9 Testing Market Diagnostics Sales by Major Supplier
France, CA 125 Testing Market Diagnostics Sales by Major Supplier
France, CEA Testing Market Diagnostics Sales by Major Supplier
France, NSE Testing Market Diagnostics Sales by Major Supplier
France, PAP Testing Market Diagnostics Sales by Major Supplier
France, PSA Testing Market Diagnostics Sales by Major Supplier